Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 208,298,848
  • Shares Outstanding, K 3,100,608
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • EBIT $ 9,201 M
  • EBITDA $ 14,588 M
  • 60-Month Beta 0.45
  • Price/Sales 4.48
  • Price/Cash Flow 12.34
  • Price/Book 5.06

Options Overview Details

View History
  • Implied Volatility 21.77% ( -0.27%)
  • Historical Volatility 30.07%
  • IV Percentile 48%
  • IV Rank 31.57%
  • IV High 34.77% on 10/31/24
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.75
  • Today's Volume 3,026
  • Volume Avg (30-Day) 10,773
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 175,228
  • Open Int (30-Day) 160,834

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.06
  • Number of Estimates 6
  • High Estimate 1.21
  • Low Estimate 0.97
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +45.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.75 +7.06%
on 11/18/24
69.00 -2.63%
on 12/09/24
+3.95 (+6.25%)
since 11/15/24
3-Month
62.75 +7.06%
on 11/18/24
79.76 -15.77%
on 10/02/24
-11.35 (-14.45%)
since 09/17/24
52-Week
60.47 +11.10%
on 02/12/24
87.68 -23.38%
on 08/30/24
+2.38 (+3.67%)
since 12/15/23

Most Recent Stories

More News
3 Unstoppable Stocks to Buy Right Now

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter...

AZN : 67.18 (+1.43%)
VRTX : 469.24 (+0.25%)
LLY : 778.62 (-0.05%)
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression...

AZN : 67.18 (+1.43%)
NVO : 108.01 (-0.04%)
LLY : 778.62 (-0.05%)
3 Penny Stocks With 10% to 210% Upside Potential

Investors should consider these three penny stocks for their solid upside potential, even after this year's rally.

CGEN : 1.5900 (unch)
MAPS : 1.2200 (+9.91%)
AZN : 67.18 (+1.43%)
$SPX : 6,050.61 (-0.39%)
GCG25 : 2,662.8 (+0.03%)
NGD : 2.66 (-1.48%)
GILD : 92.80 (+0.81%)
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation (BTD) to their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd),...

AZN : 67.18 (+1.43%)
MRK : 100.06 (unch)
PFE : 26.43 (+4.67%)
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi (durvalumab),...

AZN : 67.18 (+1.43%)
EXEL : 34.69 (-3.83%)
GILD : 92.80 (+0.81%)
PFE : 26.43 (+4.67%)
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer

Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.

KO : 63.40 (+1.36%)
AZN : 67.18 (+1.43%)
AMGN : 265.95 (-0.21%)
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ

This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s...

AZN : 67.18 (+1.43%)
JNJ : 146.41 (+1.78%)
MRK : 100.06 (unch)
LLY : 778.62 (-0.05%)
RHHBY : 35.8400 (+0.84%)
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC

Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for the treatment of certain patients with non-small cell lung cancer (NSCLC).The...

AZN : 67.18 (+1.43%)
MRK : 100.06 (unch)
ABBV : 175.38 (+2.18%)
PFE : 26.43 (+4.67%)
3 Momentum Stocks Soaring Into 2025 and Beyond

Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.

MSTR : 386.42 (-5.41%)
SEZL : 315.18 (-3.66%)
AZN : 67.18 (+1.43%)
MNPR : 30.68 (+14.91%)
The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks

For Immediate ReleaseChicago, IL – December 2, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

ANET : 112.95 (-3.07%)
CVX : 148.11 (-0.84%)
AZN : 67.18 (+1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 68.65
2nd Resistance Point 68.06
1st Resistance Point 67.62
Last Price 67.18
1st Support Level 66.59
2nd Support Level 66.00
3rd Support Level 65.56

See More

52-Week High 87.68
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
Last Price 67.18
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar